Recent preclinical and clinical evidence has shown promise in treating cancer by utilizing anti-CTLA4 antibodies (7–10); however, the clinical trial for solid tumors achieved very limited success because of the weak anti-tumor T cell immune responses, it is very challenging to establish the effective anti-tumor response in solid tumors due to its immunosuppressive TME. Here, CTLA4 is linked to neoplasm.